Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 118

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 118
---
 Sheet, Oncotelic could receive up to an additional $15.0 million in shares of common
stock of Mosaic that would be valued at the time of issuance if certain milestones are achieved (see Note 13 to the accompanying consolidated
financial statements), which would cause substantial additional dilution to existing stockholders.

We currently have no development pipeline and we
may not successfully identify, license or acquire new product candidates.

The success of our business over the near term depends
upon our ability to identify and validate new potential cancer therapeutics, including the technology we intend to acquire under the Binding
Term Sheet. Efforts to identify new product candidates require substantial technical, financial and human resources, and our limited financial
resources combined with our methodology may not successfully identify medically relevant potential therapeutics to be developed as product
candidates. Moreover, our research and business development efforts may identify molecules that initially show promise yet fail to yield
product candidates for clinical development for multiple reasons. For example, potential product candidates may, on further study, be
shown to have inadequate efficacy, harmful side effects, suboptimal drug profiles, suboptimal manufacturability or stability, or other
characteristics suggesting that they are unlikely to be commercially viable products. Our inability to successfully identify additional
new product candidates to advance into clinical trials could have a material adverse effect on our business, financial condition, results
of operations and prospects.

 10 

If we are able to raise sufficient capital and
successfully identify new product candidates, we expect that we will incur significant losses over the next several years and may never
achieve or maintain profitability. 

We have limited our operations in advancing our technology
based on the limited amount of capital we have raised. Since the reverse merger in August 2020, we have not raised any capital other than
$575,000 and $341,632 from the issuance of our convertible notes in May 2021 and February 2022, respectively. Due to our limited operations,
our historical results do not reflect the significant costs required to develop a product candidate. In addition, the products we have
previously developed were in preclinical development and any future product may likely be in preclinical development. Therefore, pending
our ability to raise sufficient capital, we anticipate that our expenses will increase substantially over the next several years, if and
as we:

    ·
    identify and successfully license or acquire new product candidates or technologies;

    ·
    develop product manufacturing processes under the Food and Drug Administration’s (“FDA